Fox Chase Researchers Find Ripretinib Significantly Improves Survival for Patients With Advanced Gastrointestinal Tumors
PHILADELPHIA (September 24, 2020)—Researchers at Fox Chase Cancer Center recently published the results of an international study showing improved survival for patients with advanced gastrointestinal stromal tumors who used ripretinib (Qinlock) when compared with patients taking a placebo.